NRI Brownsville is a medicare approved dialysis facility center in Brownsville, Texas and it has 20 dialysis stations. It is located in Cameron county at 2945 Central Blvd, Brownsville, TX, 78520. You can reach out to the office of NRI Brownsville at (956) 542-8094. This dialysis clinic is managed and/or owned by Davita. NRI Brownsville has the following ownership type - Profit. It was first certified by medicare in April, 1996. The medicare id for this facility is 452737 and it accepts patients under medicare ESRD program.
Name | NRI Brownsville |
---|---|
Location | 2945 Central Blvd, Brownsville, Texas |
No. of Dialysis Stations | 20 |
Medicare ID | 452737 |
Managed By | Davita |
Ownership Type | Profit |
Late Shifts | No |
2945 Central Blvd, Brownsville, Texas, 78520 | |
(956) 542-8094 | |
News Archive
Results from a phase 3 clinical trial indicate that patients who have not benefited from standard therapy for ankylosing spondylitis, a chronic inflammatory disease characterized by back pain and sacroiliac-joint damage, may have another treatment option in the biologic drug ixekizumab.
A team of Cedars-Sinai Regenerative Medicine Institute researchers led by Terrence Town, Ph.D. has been awarded a three-year, $1.47 million grant from the California Institute for Regenerative Medicine to fund research into mechanisms for how human immune systems reject or accept transplanted brain stem cells.
NeuroPhage Pharmaceuticals, Inc., a company developing breakthrough therapies for neurodegenerative diseases, today announced that it raised $6.4 million in a private equity financing round.
The Jonsson Cancer Center Foundation at UCLA hosts its 16th annual Taste for a Cure Friday, April 15, 2011 at the Beverly Wilshire Hotel. This year's event honors Showtime Networks President of Entertainment, David Nevins, with the Gil Nickel Humanitarian Award.
Some men, it seems, can't get enough of luxury goods like European sports cars or designer jeans. Now, scientists have figured out why: testosterone.
› Verified 1 days ago
NPI Number | 1962458562 |
Organization Name | Brownsville Renal Center |
Doing Business As | Brownsville Kidney Center Ltd |
Address | 2945 Central Blvd Brownsville, Texas, 78520 |
Phone Number | (956) 542-8094 |
News Archive
Results from a phase 3 clinical trial indicate that patients who have not benefited from standard therapy for ankylosing spondylitis, a chronic inflammatory disease characterized by back pain and sacroiliac-joint damage, may have another treatment option in the biologic drug ixekizumab.
A team of Cedars-Sinai Regenerative Medicine Institute researchers led by Terrence Town, Ph.D. has been awarded a three-year, $1.47 million grant from the California Institute for Regenerative Medicine to fund research into mechanisms for how human immune systems reject or accept transplanted brain stem cells.
NeuroPhage Pharmaceuticals, Inc., a company developing breakthrough therapies for neurodegenerative diseases, today announced that it raised $6.4 million in a private equity financing round.
The Jonsson Cancer Center Foundation at UCLA hosts its 16th annual Taste for a Cure Friday, April 15, 2011 at the Beverly Wilshire Hotel. This year's event honors Showtime Networks President of Entertainment, David Nevins, with the Gil Nickel Humanitarian Award.
Some men, it seems, can't get enough of luxury goods like European sports cars or designer jeans. Now, scientists have figured out why: testosterone.
› Verified 1 days ago
Experience Measure | Provider | National Avg. |
---|---|---|
Patients who reported that nephrologists always communicated and cared for them. | 57% | 67% |
Patients who reported that nephrologists usually communicated and cared for them. | 17% | 15% |
Patients who reported that nephrologists sometimes or never communicated and cared for them. | 26% | 18% |
Patients who gave their nephrologists a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 38% | 60% |
Patients who gave their nephrologists a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 38% | 26% |
Patients who gave their nephrologists a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 24% | 14% |
News Archive
Results from a phase 3 clinical trial indicate that patients who have not benefited from standard therapy for ankylosing spondylitis, a chronic inflammatory disease characterized by back pain and sacroiliac-joint damage, may have another treatment option in the biologic drug ixekizumab.
A team of Cedars-Sinai Regenerative Medicine Institute researchers led by Terrence Town, Ph.D. has been awarded a three-year, $1.47 million grant from the California Institute for Regenerative Medicine to fund research into mechanisms for how human immune systems reject or accept transplanted brain stem cells.
NeuroPhage Pharmaceuticals, Inc., a company developing breakthrough therapies for neurodegenerative diseases, today announced that it raised $6.4 million in a private equity financing round.
The Jonsson Cancer Center Foundation at UCLA hosts its 16th annual Taste for a Cure Friday, April 15, 2011 at the Beverly Wilshire Hotel. This year's event honors Showtime Networks President of Entertainment, David Nevins, with the Gil Nickel Humanitarian Award.
Some men, it seems, can't get enough of luxury goods like European sports cars or designer jeans. Now, scientists have figured out why: testosterone.
› Verified 1 days ago
Experience Measure | Provider | National Avg. |
---|---|---|
Patients who reported that dialysis center staff always communicated well, kept patients comfortable and pain-free as possible. | 62% | 62% |
Patients who reported that dialysis center staff usually communicated, kept patients comfortable and pain-free as possible. | 22% | 20% |
Patients who reported that dialysis center staff sometimes or never communicated, kept patients comfortable and pain-free. | 16% | 18% |
Patients who gave their dialysis facility staff a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 61% | 62% |
Patients who gave their dialysis facility staff a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 28% | 26% |
Patients who gave their dialysis facility staff a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 11% | 12% |
News Archive
Results from a phase 3 clinical trial indicate that patients who have not benefited from standard therapy for ankylosing spondylitis, a chronic inflammatory disease characterized by back pain and sacroiliac-joint damage, may have another treatment option in the biologic drug ixekizumab.
A team of Cedars-Sinai Regenerative Medicine Institute researchers led by Terrence Town, Ph.D. has been awarded a three-year, $1.47 million grant from the California Institute for Regenerative Medicine to fund research into mechanisms for how human immune systems reject or accept transplanted brain stem cells.
NeuroPhage Pharmaceuticals, Inc., a company developing breakthrough therapies for neurodegenerative diseases, today announced that it raised $6.4 million in a private equity financing round.
The Jonsson Cancer Center Foundation at UCLA hosts its 16th annual Taste for a Cure Friday, April 15, 2011 at the Beverly Wilshire Hotel. This year's event honors Showtime Networks President of Entertainment, David Nevins, with the Gil Nickel Humanitarian Award.
Some men, it seems, can't get enough of luxury goods like European sports cars or designer jeans. Now, scientists have figured out why: testosterone.
› Verified 1 days ago
Experience Measure | Provider | National Avg. |
---|---|---|
Patients who reported that 'YES', their nephrologists and dialysis center staff provided them the information they needed to take care of them. | 80% | 80% |
Patients who reported that 'NO', their nephrologists and dialysis center staff does not provided them the information they needed to take care of them. | 20% | 20% |
Patients who gave their dialysis center a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 65% | 68% |
Patients who gave their dialysis center a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 18% | 20% |
Patients who gave their dialysis center a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 17% | 12% |
News Archive
Results from a phase 3 clinical trial indicate that patients who have not benefited from standard therapy for ankylosing spondylitis, a chronic inflammatory disease characterized by back pain and sacroiliac-joint damage, may have another treatment option in the biologic drug ixekizumab.
A team of Cedars-Sinai Regenerative Medicine Institute researchers led by Terrence Town, Ph.D. has been awarded a three-year, $1.47 million grant from the California Institute for Regenerative Medicine to fund research into mechanisms for how human immune systems reject or accept transplanted brain stem cells.
NeuroPhage Pharmaceuticals, Inc., a company developing breakthrough therapies for neurodegenerative diseases, today announced that it raised $6.4 million in a private equity financing round.
The Jonsson Cancer Center Foundation at UCLA hosts its 16th annual Taste for a Cure Friday, April 15, 2011 at the Beverly Wilshire Hotel. This year's event honors Showtime Networks President of Entertainment, David Nevins, with the Gil Nickel Humanitarian Award.
Some men, it seems, can't get enough of luxury goods like European sports cars or designer jeans. Now, scientists have figured out why: testosterone.
› Verified 1 days ago
Dialysis patients with Hemoglobin data | 85 |
Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 7 |
News Archive
Results from a phase 3 clinical trial indicate that patients who have not benefited from standard therapy for ankylosing spondylitis, a chronic inflammatory disease characterized by back pain and sacroiliac-joint damage, may have another treatment option in the biologic drug ixekizumab.
A team of Cedars-Sinai Regenerative Medicine Institute researchers led by Terrence Town, Ph.D. has been awarded a three-year, $1.47 million grant from the California Institute for Regenerative Medicine to fund research into mechanisms for how human immune systems reject or accept transplanted brain stem cells.
NeuroPhage Pharmaceuticals, Inc., a company developing breakthrough therapies for neurodegenerative diseases, today announced that it raised $6.4 million in a private equity financing round.
The Jonsson Cancer Center Foundation at UCLA hosts its 16th annual Taste for a Cure Friday, April 15, 2011 at the Beverly Wilshire Hotel. This year's event honors Showtime Networks President of Entertainment, David Nevins, with the Gil Nickel Humanitarian Award.
Some men, it seems, can't get enough of luxury goods like European sports cars or designer jeans. Now, scientists have figured out why: testosterone.
› Verified 1 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
Adult patients getting regular hemodialysis at the center | 123 |
Adult patient months included in Kt/V greater than or equal to 1.2 | 1294 |
Percentage of adult patients getting regular hemodialysis at the center | 97 |
Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
Results from a phase 3 clinical trial indicate that patients who have not benefited from standard therapy for ankylosing spondylitis, a chronic inflammatory disease characterized by back pain and sacroiliac-joint damage, may have another treatment option in the biologic drug ixekizumab.
A team of Cedars-Sinai Regenerative Medicine Institute researchers led by Terrence Town, Ph.D. has been awarded a three-year, $1.47 million grant from the California Institute for Regenerative Medicine to fund research into mechanisms for how human immune systems reject or accept transplanted brain stem cells.
NeuroPhage Pharmaceuticals, Inc., a company developing breakthrough therapies for neurodegenerative diseases, today announced that it raised $6.4 million in a private equity financing round.
The Jonsson Cancer Center Foundation at UCLA hosts its 16th annual Taste for a Cure Friday, April 15, 2011 at the Beverly Wilshire Hotel. This year's event honors Showtime Networks President of Entertainment, David Nevins, with the Gil Nickel Humanitarian Award.
Some men, it seems, can't get enough of luxury goods like European sports cars or designer jeans. Now, scientists have figured out why: testosterone.
› Verified 1 days ago
Adult patients getting regular peritoneal dialysis at the center | 12 |
Adult patient months included in Kt/V greater than or equal to 1.7 | 105 |
Percentage of adult patients getting regular peritoneal dialysis at the center | 95 |
Percentage of pediatric patients getting regular peritoneal dialysis at the center |
News Archive
Results from a phase 3 clinical trial indicate that patients who have not benefited from standard therapy for ankylosing spondylitis, a chronic inflammatory disease characterized by back pain and sacroiliac-joint damage, may have another treatment option in the biologic drug ixekizumab.
A team of Cedars-Sinai Regenerative Medicine Institute researchers led by Terrence Town, Ph.D. has been awarded a three-year, $1.47 million grant from the California Institute for Regenerative Medicine to fund research into mechanisms for how human immune systems reject or accept transplanted brain stem cells.
NeuroPhage Pharmaceuticals, Inc., a company developing breakthrough therapies for neurodegenerative diseases, today announced that it raised $6.4 million in a private equity financing round.
The Jonsson Cancer Center Foundation at UCLA hosts its 16th annual Taste for a Cure Friday, April 15, 2011 at the Beverly Wilshire Hotel. This year's event honors Showtime Networks President of Entertainment, David Nevins, with the Gil Nickel Humanitarian Award.
Some men, it seems, can't get enough of luxury goods like European sports cars or designer jeans. Now, scientists have figured out why: testosterone.
› Verified 1 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at NRI Brownsville with elevated calcium levels.
Patients with hypercalcemia | 139 |
Hypercalcemia patient months | 1459 |
Hypercalcemia patients with serumcalcium greater than 10.2 mg | 2 |
Patients with Serumphosphor | 139 |
Patients with Serumphosphor less than 3.5 mg/dL | 7 |
Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 20 |
Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 28 |
Patients with Serumphosphor from 5.6 to 7 mg/dL | 20 |
Patients with Serumphosphor greater than 7 mg/dL | 25 |
News Archive
Results from a phase 3 clinical trial indicate that patients who have not benefited from standard therapy for ankylosing spondylitis, a chronic inflammatory disease characterized by back pain and sacroiliac-joint damage, may have another treatment option in the biologic drug ixekizumab.
A team of Cedars-Sinai Regenerative Medicine Institute researchers led by Terrence Town, Ph.D. has been awarded a three-year, $1.47 million grant from the California Institute for Regenerative Medicine to fund research into mechanisms for how human immune systems reject or accept transplanted brain stem cells.
NeuroPhage Pharmaceuticals, Inc., a company developing breakthrough therapies for neurodegenerative diseases, today announced that it raised $6.4 million in a private equity financing round.
The Jonsson Cancer Center Foundation at UCLA hosts its 16th annual Taste for a Cure Friday, April 15, 2011 at the Beverly Wilshire Hotel. This year's event honors Showtime Networks President of Entertainment, David Nevins, with the Gil Nickel Humanitarian Award.
Some men, it seems, can't get enough of luxury goods like European sports cars or designer jeans. Now, scientists have figured out why: testosterone.
› Verified 1 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
Patients included in arterial venous fistula and catheter summaries | 121 |
Patient months included in arterial venous fistula and catheter summaries | 998 |
Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 71 |
Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 11 |
News Archive
Results from a phase 3 clinical trial indicate that patients who have not benefited from standard therapy for ankylosing spondylitis, a chronic inflammatory disease characterized by back pain and sacroiliac-joint damage, may have another treatment option in the biologic drug ixekizumab.
A team of Cedars-Sinai Regenerative Medicine Institute researchers led by Terrence Town, Ph.D. has been awarded a three-year, $1.47 million grant from the California Institute for Regenerative Medicine to fund research into mechanisms for how human immune systems reject or accept transplanted brain stem cells.
NeuroPhage Pharmaceuticals, Inc., a company developing breakthrough therapies for neurodegenerative diseases, today announced that it raised $6.4 million in a private equity financing round.
The Jonsson Cancer Center Foundation at UCLA hosts its 16th annual Taste for a Cure Friday, April 15, 2011 at the Beverly Wilshire Hotel. This year's event honors Showtime Networks President of Entertainment, David Nevins, with the Gil Nickel Humanitarian Award.
Some men, it seems, can't get enough of luxury goods like European sports cars or designer jeans. Now, scientists have figured out why: testosterone.
› Verified 1 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
Patients in facility's Hospitalization Summary | 134 |
Hospitalization Rate in facility | 152.4 (As Expected) |
Hospitalization Rate: Upper Confidence Limit | 242.2 |
Hospitalization Rate: Lower Confidence Limit | 102.8 |
News Archive
Results from a phase 3 clinical trial indicate that patients who have not benefited from standard therapy for ankylosing spondylitis, a chronic inflammatory disease characterized by back pain and sacroiliac-joint damage, may have another treatment option in the biologic drug ixekizumab.
A team of Cedars-Sinai Regenerative Medicine Institute researchers led by Terrence Town, Ph.D. has been awarded a three-year, $1.47 million grant from the California Institute for Regenerative Medicine to fund research into mechanisms for how human immune systems reject or accept transplanted brain stem cells.
NeuroPhage Pharmaceuticals, Inc., a company developing breakthrough therapies for neurodegenerative diseases, today announced that it raised $6.4 million in a private equity financing round.
The Jonsson Cancer Center Foundation at UCLA hosts its 16th annual Taste for a Cure Friday, April 15, 2011 at the Beverly Wilshire Hotel. This year's event honors Showtime Networks President of Entertainment, David Nevins, with the Gil Nickel Humanitarian Award.
Some men, it seems, can't get enough of luxury goods like European sports cars or designer jeans. Now, scientists have figured out why: testosterone.
› Verified 1 days ago
The rate of readmission show you whether patients who were being treated regularly at NRI Brownsville were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
Readmission Rate in facility | 19.9 (As Expected) |
Readmission Rate: Upper Confidence Limit | 26.9 |
Readmission Rate: Lower Confidence Limit | 14.1 |
News Archive
Results from a phase 3 clinical trial indicate that patients who have not benefited from standard therapy for ankylosing spondylitis, a chronic inflammatory disease characterized by back pain and sacroiliac-joint damage, may have another treatment option in the biologic drug ixekizumab.
A team of Cedars-Sinai Regenerative Medicine Institute researchers led by Terrence Town, Ph.D. has been awarded a three-year, $1.47 million grant from the California Institute for Regenerative Medicine to fund research into mechanisms for how human immune systems reject or accept transplanted brain stem cells.
NeuroPhage Pharmaceuticals, Inc., a company developing breakthrough therapies for neurodegenerative diseases, today announced that it raised $6.4 million in a private equity financing round.
The Jonsson Cancer Center Foundation at UCLA hosts its 16th annual Taste for a Cure Friday, April 15, 2011 at the Beverly Wilshire Hotel. This year's event honors Showtime Networks President of Entertainment, David Nevins, with the Gil Nickel Humanitarian Award.
Some men, it seems, can't get enough of luxury goods like European sports cars or designer jeans. Now, scientists have figured out why: testosterone.
› Verified 1 days ago
Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at NRI Brownsville get infections in their blood each year compared to the number of infections expected for the center based on the national average.
Standard Infection Summary Ratio(SIR) Year | January, 2016 - December, 2016 |
Infection Rate in facility | 1.33 (As Expected) |
SIR: Upper Confidence Limit | 2.22 |
SIR: Lower Confidence Limit | .74 |
News Archive
Results from a phase 3 clinical trial indicate that patients who have not benefited from standard therapy for ankylosing spondylitis, a chronic inflammatory disease characterized by back pain and sacroiliac-joint damage, may have another treatment option in the biologic drug ixekizumab.
A team of Cedars-Sinai Regenerative Medicine Institute researchers led by Terrence Town, Ph.D. has been awarded a three-year, $1.47 million grant from the California Institute for Regenerative Medicine to fund research into mechanisms for how human immune systems reject or accept transplanted brain stem cells.
NeuroPhage Pharmaceuticals, Inc., a company developing breakthrough therapies for neurodegenerative diseases, today announced that it raised $6.4 million in a private equity financing round.
The Jonsson Cancer Center Foundation at UCLA hosts its 16th annual Taste for a Cure Friday, April 15, 2011 at the Beverly Wilshire Hotel. This year's event honors Showtime Networks President of Entertainment, David Nevins, with the Gil Nickel Humanitarian Award.
Some men, it seems, can't get enough of luxury goods like European sports cars or designer jeans. Now, scientists have figured out why: testosterone.
› Verified 1 days ago
Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether NRI Brownsville's rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.
Standard Transfusion Summary Ratio (STrR) Year | January, 2016 - December, 2016 |
Patients in facility's Transfusion Summary | 124 |
Transfusion Rate in facility | 32.6 (As Expected) |
Transfusion Rate: Upper Confidence Limit | 63.6 |
Transfusion Rate: Lower Confidence Limit | 18.2 |
News Archive
Results from a phase 3 clinical trial indicate that patients who have not benefited from standard therapy for ankylosing spondylitis, a chronic inflammatory disease characterized by back pain and sacroiliac-joint damage, may have another treatment option in the biologic drug ixekizumab.
A team of Cedars-Sinai Regenerative Medicine Institute researchers led by Terrence Town, Ph.D. has been awarded a three-year, $1.47 million grant from the California Institute for Regenerative Medicine to fund research into mechanisms for how human immune systems reject or accept transplanted brain stem cells.
NeuroPhage Pharmaceuticals, Inc., a company developing breakthrough therapies for neurodegenerative diseases, today announced that it raised $6.4 million in a private equity financing round.
The Jonsson Cancer Center Foundation at UCLA hosts its 16th annual Taste for a Cure Friday, April 15, 2011 at the Beverly Wilshire Hotel. This year's event honors Showtime Networks President of Entertainment, David Nevins, with the Gil Nickel Humanitarian Award.
Some men, it seems, can't get enough of luxury goods like European sports cars or designer jeans. Now, scientists have figured out why: testosterone.
› Verified 1 days ago
The rate of mortality show you whether patients who were being treated regularly at NRI Brownsville lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.
Standard Survival Summary Ratio(SIR) Year | January, 2013 - December, 2016 |
Patients in facility's Survival Summary | 705 |
Mortality Rate in facility | 22.7 (Worse than Expected) |
Mortality Rate: Upper Confidence Limit | 27.8 |
Mortality Rate: Lower Confidence Limit | 18.3 |
News Archive
Results from a phase 3 clinical trial indicate that patients who have not benefited from standard therapy for ankylosing spondylitis, a chronic inflammatory disease characterized by back pain and sacroiliac-joint damage, may have another treatment option in the biologic drug ixekizumab.
A team of Cedars-Sinai Regenerative Medicine Institute researchers led by Terrence Town, Ph.D. has been awarded a three-year, $1.47 million grant from the California Institute for Regenerative Medicine to fund research into mechanisms for how human immune systems reject or accept transplanted brain stem cells.
NeuroPhage Pharmaceuticals, Inc., a company developing breakthrough therapies for neurodegenerative diseases, today announced that it raised $6.4 million in a private equity financing round.
The Jonsson Cancer Center Foundation at UCLA hosts its 16th annual Taste for a Cure Friday, April 15, 2011 at the Beverly Wilshire Hotel. This year's event honors Showtime Networks President of Entertainment, David Nevins, with the Gil Nickel Humanitarian Award.
Some men, it seems, can't get enough of luxury goods like European sports cars or designer jeans. Now, scientists have figured out why: testosterone.
› Verified 1 days ago
FMC Dialysis Services Of North Brownsville Location: 1900 N. Expressway, Suite E, Brownsville, Texas, 78521 Phone: (956) 504-5045 |
Fresenius Medical Care South Price Location: 64 S Price Rd, Brownsville, Texas, 78521 Phone: (956) 544-0711 |
News Archive
Results from a phase 3 clinical trial indicate that patients who have not benefited from standard therapy for ankylosing spondylitis, a chronic inflammatory disease characterized by back pain and sacroiliac-joint damage, may have another treatment option in the biologic drug ixekizumab.
A team of Cedars-Sinai Regenerative Medicine Institute researchers led by Terrence Town, Ph.D. has been awarded a three-year, $1.47 million grant from the California Institute for Regenerative Medicine to fund research into mechanisms for how human immune systems reject or accept transplanted brain stem cells.
NeuroPhage Pharmaceuticals, Inc., a company developing breakthrough therapies for neurodegenerative diseases, today announced that it raised $6.4 million in a private equity financing round.
The Jonsson Cancer Center Foundation at UCLA hosts its 16th annual Taste for a Cure Friday, April 15, 2011 at the Beverly Wilshire Hotel. This year's event honors Showtime Networks President of Entertainment, David Nevins, with the Gil Nickel Humanitarian Award.
Some men, it seems, can't get enough of luxury goods like European sports cars or designer jeans. Now, scientists have figured out why: testosterone.
› Verified 1 days ago